At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
E7080 capsuledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer
In Brief
A Phase 2 clinical trial evaluating E7080 capsule for Thyroid Cancer. Completed, enrolled 51 participants across 3 sites.
Detailed Summary
This study is to evaluate the safety, efficacy, and pharmacokinetics of E7080 when orally administered once daily (QD) in subjects with advanced thyroid cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancer
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2012
First PostedNov 2012
Primary CompletionJul 2015
Study CompletionOct 2015
TodayJul 2026
First PostedNov 20, 2012
Enrollment StartSep 3, 2012
Primary CompletionJul 9, 2015
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.6 years ago
Interventions
E7080 capsuledrug
E7080 is administered as continuous once daily dosing in an uncontrolled manner